The 22 references in paper R. Alyautdin N., B. Romanov K., A. Pereverzev P., A. Chikalo O., N. Bunyatyan D., V. Merkulov A., A. Mironov N., Р. Аляутдин Н., Б. Романов К., А. Переверзев П., А. Чикало О., Н. Бунятян Д., В. Меркулов А., А. Миронов Н. (2018) “Алипоген типарвовек: долгая дорога к оценке отношения пользы и риска генотерапевтического препарата // Alipogene tiparvovec: a long journey of risk-benefit ratio assessment of gene therapy products” / spz:neicon:vedomostincesmp:y:2015:i:1:p:31-34

1
Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K. Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. J. of Nanomed. 2014; (9): 2539–55.
(check this in PDF content)
2
Alyautdin R, Kreuter J, Kharkevich DA. Brain drug delivery using nanoparticles. Experimentalnaya i klinicheskaya farmakologiya 2003; (66): 65–68 (in Russian).
(check this in PDF content)
3
Bryant LM, Christopher DM, Giles AR, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013; (24): 55–64.
(check this in PDF content)
4
Nierman MC, Rip J, Twick J. Gene therapy for genetic lipoprotein lipase deficiency: from promise to practice. The Netherlands J. of Med. 2005; (63): 14–22.
(check this in PDF content)
5
Kimura W, Mossner J. Role of hypertriglyceridemia in the pathogenesis of experimental acute pancreatitis in rats. Int J Pancreatol. 1996; (20): 177–184.
(check this in PDF content)
6
Weber CK, Adler G. From Acinar Cell Damage to Systemic Inflammatory Response: Current Concepts in Pancreatitis. Pancreatology 2001; (1): 356–62.
(check this in PDF content)
7
Bach AC, Babayan VK. Medium-chain triglycerides: an update. Am J Clin Nutr. 1982; (36): 950–62.
(check this in PDF content)
8
Durrington P. Dyslipidaemia. Lancet 2003; (362): 717–31.
(check this in PDF content)
9
Eckel R.H. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med. 1989; (320): 1060–68.
(check this in PDF content)
10
Effects of lovaza on lipoprotein composition and function in mild hypertriglyceridemia (ELLF). Available from: http://clinicaltrials.gov/ct2/show/ NCT00901979.
(check this in PDF content)
11
Dam M, Stalenhoef AF, Wittekoek J. Efficacy of concentrated n-3 Fatty acids in hypertriglyceridaemia: a comparison with gemfibrozil. Clin Drug Invest. 2001; (21): 175–81.
(check this in PDF content)
12
Shyam D, Berns KI. Gene therapy using adeno-associated virus vector. Clin Microbiol Review 2008; (43): 583–93.
(check this in PDF content)
13
Supotnitskiy MV. Viral vector based gene therapeutic systems. Biopreparaty 2011; (3): 15–26 (in Russian).
(check this in PDF content)
14
Gruntman AM, Bish LT, Mueller C, et.al. Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Prot Microbiol 2013; (14): 3–12.
(check this in PDF content)
15
Fisher KJ, Jooss K, Alston J. Recombinant adeno-associated for muscle directed gene therapy. Nat Med. 1997; (3): 306–31.
(check this in PDF content)
16
Rip J, Nierman MC, Jukema JW, et al. Lipoprotein lipase S447X – a naturellyoccurring gain-of-function. Arter Thromb Vasc Biol. 2006; (6): 1236–45.
(check this in PDF content)
17
Wang D, Zhong L, Abu Nahid M, et al. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv. 2014; (11): 345–64.
(check this in PDF content)
18
Burnett J, Hooper AJ. Alipogene tiparvovec, an adeno-associated virus encoding the Ser447X variant of the human lipoprotein lipase gene for the treanment of patients with lipoprotein lipase deficiency. Curr Opinion in Mol Ther. 2009; (11): 681–91.
(check this in PDF content)
19
Ross CJ, Liu G, Kuenvenhoven JA, et al. Complete rescue of lipoprotein lipasedeficient mice by somatic gene transfer of the naturally occurring LPL beneficial mutation. Arter Thromb Vasc Biol. 2005; (25): 2143–50.
(check this in PDF content)
20
Ross CJ, Twisk J, Bakker AC, et al. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-vediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther 2006; (17): 487–99.
(check this in PDF content)
21
Ferreira V, Petry H, Salmon F. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. Front Immunol. 2014; (5): 82–85.
(check this in PDF content)
22
Buning H. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med. 2013; (5): 1–3. R E F E R E N C E S Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation, 8 Petrovsky
(check this in PDF content)